Utilization of sacubitril/valsartan in patients with heart failure with reduced ejection fraction: real-world data from the ARIADNE registry
| Autor: | Ariadne investigators, Andrew L. Clark, Cornelia Koch, Aldo P. Maggioni, Thibaud Damy, Vivencio Barrios, Lars Lund, Candisda Fonseca, Stefanie Kalus, Jarosław Drożdż, Uwe Zeymer, Rizwan I Hussain, Philippe Ferber |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
medicine.medical_specialty Adolescent MEDLINE Tetrazoles Angiotensin-Converting Enzyme Inhibitors 030204 cardiovascular system & hematology Ventricular Function Left 03 medical and health sciences Angiotensin Receptor Antagonists Ventricular Dysfunction Left 0302 clinical medicine Text mining Internal medicine Medicine Humans In patient 030212 general & internal medicine Registries Aged Heart Failure Ejection fraction business.industry Health Policy Aminobutyrates Biphenyl Compounds Stroke Volume medicine.disease Treatment Outcome Heart failure Cardiology Valsartan Cardiology and Cardiovascular Medicine business Real world data Sacubitril Valsartan |
| Zdroj: | European heart journal. Quality of careclinical outcomes. 8(4) |
| ISSN: | 2058-1742 |
| Popis: | Aims To compare baseline characteristics of patients with heart failure with reduced ejection fraction (HFrEF) initiated on sacubitril/valsartan compared with patients continued on conventional heart failure (HF)-treatment in a European out-patient setting. Methods and results Between July 2016 and July 2019, ARIADNE enrolled 8787 outpatients aged ≥18 years with HFrEF from 17 European countries. Choice of therapy was solely at the investigators’ discretion. In total, 4173 patients were on conventional HF-treatment (non-S/V group), while 4614 patients were on sacubitril/valsartan either at enrolment or started sacubitril/valsartan within 1 month of enrolment (S/V group). Of these, 2108 patients started sacubitril/valsartan treatment ±1 month around enrolment [restricted S/V (rS/V) group]. The average age of the patients was 68 years. Patients on S/V were more likely to have New York Heart Association (NYHA) class III or IV symptoms (50.3%, 44.6%, 32.1% in rS/V, S/V, and non-S/V, respectively) and had lower left ventricular ejection fraction (LVEF; 32.3%, 32.7%, and 35.4% in rS/V, S/V, and non-S/V, respectively; P Conclusion In this large multinational HFrEF registry, patients receiving sacubitril/valsartan tended to be younger with lower LVEF and higher NYHA class. Fewer than half of the patients received triple HF therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|